Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Rectal Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Stomach Neoplasms 1Sarcoma 1Recurrence 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Colonic Neoplasms 1

Interventions

Bevacizumab 187Fluorouracil 150Leucovorin 135Cetuximab 127Irinotecan 114Oxaliplatin 108pembrolizumab 96Capecitabine 82IFL protocol 53Panitumumab 43Nivolumab 43regorafenib 42Folfox protocol 39Gemcitabine 30trifluridine tipiracil drug combination 27Cisplatin 24Carboplatin 24atezolizumab 23Pemetrexed 20Paclitaxel 20Drug Therapy 20130-nm albumin-bound paclitaxel 17Trastuzumab 14encorafenib 13Trifluridine 13Ipilimumab 13HMPL-013 13tislelizumab 12spartalizumab 11Docetaxel 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Colorectal Neoplasms × Immunoconjugates × Clear all
NCT01605318 2024-01-24

Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer

Gilead Sciences

Phase 1/2 Terminated
92 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01915472 2021-08-19

A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer

Gilead Sciences

Phase 2 Withdrawn
Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡